CRUSH
Hypophosphatemia

PHOXILLUM renal replacement solution is shown to reduce hypophosphatemia,1 solution preparation time,2,3 and potential for errors4* when treating acute kidney injury (AKI) patients.

*Due to manual compounding

The Impact of Persistent Hypophosphatemia During CRRT on ICU Outcomes

50-80%

of patients develop hypophosphatemia during RRT5-7, and even patients with initial hyperphosphatemia may become hypophosphatemic when phosphate-free solutions are used8

81%

increase in prolonged respiratory failure requiring tracheostomy [(OR) = 1.81; 95% CI 1.07-3.08]9

1.45-fold

increase in 28-day mortality with patients who experienced “high frequency” hypophosphatemia (≥ 58% of therapy days, p= 0.008)

PHOXILLUM is the ONLY FDA-approved premixed CRRT replacement solution with phosphate in a 5L bag.

Phoxillum provides significantly reduced hyphosphatemia in patients compared to PRISMASOL

Reduced Hypophosphatemia

Multiple studies around the globe have shown that phosphate-containing solutions reduce phosphatemia. A US retrospective analysis of 60 patients comparing PHOXILLUM to PRISMASOL solution in CVVH showed that patients treated with PHOXILLUM had:1

  • Significantly fewer treatment days with hypophosphatemia (24.9% vs. 6.3%, p < 0.0001)
  • Significantly fewer days of intravenous phosphate repletion (5.5% vs. 1.9%, p = 0.013)
 PHOXILLUM costs $35.61 Compared to Prismasol at $35.34

Pre-mixed Solutions = Less Preparation Time Without Necessarily More Expense

A study of CRRT solutions that included (1) PHOXILLUM solution with no electrolyte additives, (2)  PHOXILLUM solution with added bicarbonate, and (3) PRISMASOL solution with added potassium chloride and sodium phosphate (control) showed:**
  • Significantly reduced average technician time with the current PHOXILLUM bag design (45 sec. vs 179 sec with PRISMASOL solution, p < 0.0001 for both comparisons)3
  • Similar final costs for PHOXILLUM and PRISMASOL solutions (Final costs included base solution, additives, supplies, and personnel per 5L bag)2
 
this chart shows the number of errors reported and level of harm reported

Fewer Errors Are Reported With Pre-mixed CRRT Solutions

An Internet survey of CRRT medication errors in 31 programs reported:10

  • 58% of programs reported at least one error (2 anticoagulation, 16 compounding)
  • 89% of reported CRRT solution errors were due to compounding
  • All errors occurred in manually-prepared solutions; 0 errors were observed in pre-mixed commercial solutions
  • 56% of compounding errors resulted in patient harm
Featured Presentation
Dr. Melissa Thompson-Bastin discusses managing phosphate levels and preventing hypophosphatemia in CRRT, as well as how and when to implement Baxter's renal replacement solutions.

Preventing Hypophosphatemia and Improving Patient Outcomes in CRRT

Dr. Melissa Thompson Bastin discusses managing phosphate levels and preventing hypophosphatemia in CRRT, as well as how and when to implement Baxter's renal replacement solutions.

** Please note that the only approved additives are:

PHOXILLUM Solution: phosphate up to 0.2  mmol/L sodium phosphate not to exceed 1.2 mmol/L.

PRISMASOL Solution: up to 1.2 mmol/L of phosphate added as potassium phosphate or sodium phosphate. Total potassium should not exceed 4 mEq/L. 

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

 

Indications and Usage 
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.


Warnings and Precautions 
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.